Speed Up Vital Research! Donate Now!

NPF Announcements

Free Webinar: Managing Common Health Concerns  When You Have Parkinson'sFree Webinar: Managing Common Health Concerns When You Have Parkinson's

Register now to join the National Parkinson Foundation on Thursday, February 26 at 1:00 p.m. ET for a special webinar discussing how arthritis, diabetes, the common cold and other ailments affect your Parkinson's disease.

FDA Approval of DUOPA, a Revolutionary Parkinson's Treatment

The U.S. Food and Drug Administration (FDA) has approved DUOPA™, developed by AbbVie Inc., as a treatment for people with advanced Parkinson's disease. DUOPA™ is a new approach to the delivery of carbidopa and levodopa for the treatment of the motor symptoms of Parkinson's disease; it is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine.

Advancing Research for Neurological Diseases Act IntroducedAdvancing Research for Neurological Diseases Act Introduced

Take action for people with Parkinson’s! Tell your Representative to sponsor HR 292, which would create a data collection system for Parkinson’s and other neurological diseases.

FDA Approval of RYTARY™ (Carbidopa and Levodopa) Extended-Release Capsules for the Treatment of Parkinson's diseaseFDA Approval of RYTARY™ (Carbidopa and Levodopa) Extended-Release Capsules for the Treatment of Parkinson's disease

Impax Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) approved RYTARY, an extended-release oral capsule formulation of carbidopa-levodopa, for the treatment of Parkinson's disease.